Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(17%)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
5
83%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
5(83.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (83.3%)
Phase 31 (16.7%)

Trials by Status

terminated117%
unknown117%
completed350%
withdrawn117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_2

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

NCT05017480
completedphase_2

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

NCT04773678
unknownphase_2

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

NCT05905133
terminatedphase_2

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

NCT04783389
completedphase_2

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT04444752
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05017480Phase 2

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

Completed
NCT04773678Phase 2

Efficacy and Safety of CBP-201 in Patients With Moderate to Severe Persistent Asthma With Type 2 Inflammation

Completed
NCT05905133Phase 2

A Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe AD

Unknown
NCT04783389Phase 2

A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps

Terminated
NCT04444752Phase 2

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Completed
NCT05614817Phase 3

CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6